Peroxisome proliferator-activated receptor (PPAR)γ is highly expressed in normal human pituitary gland

Journal of Endocrinological Investigation

Volumn 28, Issue 10, 2005, Pages 899-904

  Bogazzi, F ^a   Russo, D ^a   Locci, M T ^a   Chifenti, B ^a   Ultimieri, F ^a   Raggi, F ^a   Viacava, P ^a   Cecchetti, D ^a   Cosci, C ^a   Sardella, C ^a   Acerbi, G ^a   Gasperi, M ^a   Martino, E ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Immunofluorescence; Pituitary; PPAR

Indexed keywords

CORTICOTROPIN; FOLLITROPIN; GROWTH HORMONE; LUTEINIZING HORMONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROLACTIN; THYROTROPIN;

ADENOMA; ADULT; AGED; ARTICLE; CANCER SURGERY; CELL NUCLEUS; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CYTOPLASM; FEMALE; HUMAN; HUMAN TISSUE; HYPOPHYSIS; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 31544472854     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03345321     Document Type: Article

References (18)

1. Desvergne B, Wahli W. Peroxisome proliferator activated receptors: nuclear control of metabolism. Endocr Rev 1999, 20: 649-88.
2. Rangwala SM, Lazar MA. Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci 2004, 25: 331-6.
3. Lowell BB. PPARγ: an essential regulator of adipogenesis and modulator of fat cell function. Cell 1999, 99: 239-42.
4. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2000, 106: 523-31.
5. Sporn MB, Suh N, Mangelsdorf DJ. Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). Trends Mol Med 2001, 7: 395-400.
6. Demetri GD, Fletcher CDM, Mueller E, et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 1999, 96: 3951-6.
7. Kubota T, Koshizuka K, Williamson EA, et al. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998, 58: 3344-52.
8. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004, 10: 355-61.
9. Zander T, Kraus JA, Grommes C, et al. Induction of apoptosis in human and rat glioma by antagonist of the nuclear receptor PPARgamma. J Neurochem 2002, 81: 1052-60.
10. Ohta K, Endo T, Haraguchi K, et al. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 2001, 86: 2170-7.
11. Desvergne B, Michalik L, Whali W. Be fit or be sick: peroxisome proliferator-activated receptors are down the road. Mol Endocrinol 2004, 18: 1321-2.
12. Moller DE, Berger JP. Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation. Int J Obes Relat Metab Disord 2003, 3: S17-21.
13. Heaney AP, Fernando M, Yong WH, Melmed S. Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med 2002, 8: 1281-7.
14. Heaney AP, Fernando M, Melmed S. PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. J Clin Invest 2003, 111: 1381-8.
15. Bogazzi F, Ultimieri F, Raggi F, et al. PPARγ inhibits GH syntesis and secretion and increases apoptosis of pituitary GH-secreting adenomas. Eur J Endocrinol 2004, 150: 863-75.
16. Ambrosi B, Dall'Asta C, Cannavo S, et al. Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. Eur J Endocrinol 2004, 151: 173-8.
17. Cannavo' S, Ambrosi B, Chiodini I, et al. Baseline and CRH-stimulated ACTH and cortisol levels after administration of the peroxisome proliferator-activated receptor-gamma ligand, rosiglitazone, in Cushing's disease. J Endocrinol Invest 2004, 27: RC8-11.
18. Shibuya A, Wada K, Nakajima A, et al. Nitration of PPARg inhibits ligand-dependent translocation into the nucleus in a macrophage-like cell line, RAW 264. FEBS Letters 2002, 525: 43-7.